Welcome to our dedicated page for Greenwich Lifesciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures often bury the details that matter—trial safety data, R&D burn, and potential share dilution—deep inside technical exhibits. Greenwich Lifesciences Inc’s 10-K and 8-K filings are no exception; they weave GP2 immunotherapy trial results with nuanced FDA guidance that can span hundreds of pages. If you’ve ever wondered “how do I locate Greenwich Lifesciences’ Phase III milestones in a single place?” this page is built for you.
Stock Titan surfaces every report the moment it hits EDGAR and then lets our AI turn dense language into concise explanations. Need the Greenwich Lifesciences quarterly earnings report 10-Q filing broken down to cash runway and trial endpoints? Or instant alerts on Greenwich Lifesciences insider trading Form 4 transactions? Simply open the filing — our engine delivers context plus plain-English definitions. You’ll also find Greenwich Lifesciences Form 4 insider transactions real-time, Greenwich Lifesciences executive stock transactions Form 4, and Greenwich Lifesciences proxy statement executive compensation mapped to easy charts. Greenwich Lifesciences SEC filings explained simply sit beside the original PDF.
Whether you’re screening for financing risk or tracking when a new GP2 cohort is disclosed, our coverage spans every form type. Scan Greenwich Lifesciences annual report 10-K simplified for pipeline updates, review Greenwich Lifesciences 8-K material events explained within minutes, or dive into Greenwich Lifesciences earnings report filing analysis with side-by-side quarter comparisons. For anyone understanding Greenwich Lifesciences SEC documents with AI, this hub turns regulatory complexity into actionable insight.
Greenwich LifeSciences, Inc. reported the results of its Annual Meeting of Stockholders held on December 18, 2025. A total of 8,944,615 shares of common stock were represented in person or by proxy, satisfying quorum requirements.
Stockholders elected all five director nominees — David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock — to serve until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Each nominee received over 7.1 million votes “for,” with no votes “against,” and varying abstentions, alongside broker non-votes.
Stockholders also ratified the appointment of MaloneBailey LLP as the company’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 8,908,299 votes “for,” 31,459 “against,” and 4,857 “abstain.”
Greenwich LifeSciences, Inc. (GLSI)Snehal Patel received a grant of 100,000 stock options on 11/13/2025. These options have an exercise price of $8.2 per share and are exercisable into 100,000 shares of common stock, with an expiration date of 11/13/2035. Following this grant, Patel beneficially owns 2,347,462 derivative securities directly.
Greenwich LifeSciences (GLSI) reported Q3 2025 results with no revenue and a net loss of
Cash was
Management disclosed substantial doubt about the company’s ability to continue as a going concern and reported material weaknesses in internal controls. The Phase III Flamingo‑01 trial of GLSI‑100 continues as the core operating focus.
Greenwich LifeSciences (GLSI) reported an insider open‑market purchase. Snehal Patel acquired 10,600 shares of common stock at $8.43 on 11/07/2025. After this transaction, his beneficial ownership stands at 5,583,502 shares, held directly.
Patel is the company’s CEO, CFO, a director, and a 10% owner. The report reflects one reporting person and lists the transaction in Table I; no derivative transactions are shown in Table II.
Greenwich LifeSciences (GLSI): Insider purchase reported. CEO, CFO and Director Snehal Patel, a 10% owner, bought 2,300 shares of common stock on 10/31/2025 at $9.26 per share. Following this transaction, he beneficially owned 5,572,902 shares, reported as direct ownership.
Greenwich LifeSciences will hold its Annual Meeting on December 18, 2025 at 9:00 a.m. local time in New York to elect five directors and ratify MaloneBailey LLP as independent auditor for fiscal 2025.
The record date is October 28, 2025, with 13,854,539 shares outstanding; a quorum requires 6,927,270 shares represented. Directors are elected by a plurality of votes cast, while auditor ratification requires a majority of shares present and entitled to vote.
Ownership is concentrated: CEO Snehal Patel beneficially owns 6,074,953 shares (
FAQ
What is the current stock price of Greenwich Lifesciences (GLSI)?
What is the market cap of Greenwich Lifesciences (GLSI)?
